Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next

Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next

Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

Failure is very profitable for Pain Therapeutics CEO Remi Barbier.

Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data

Biotech School: How to Spot Hidden Danger Signs in Clinical Trial Data

Using Northwest Bio as an example, I'm going to teach you how to read clinical trial data to find red flags and bad stuff biotechs don't want you to see.

Axovant Sinks on Rival's Alzheimer's Drug Setback

Axovant Sinks on Rival's Alzheimer's Drug Setback

An Alzheimer's drug under development by Danish pharma Lundbeck failed a pivotal phase III study and Axovant suffered collateral damage.

Cloudy Outlook for Aerie Pharma's Glaucoma Drug

Cloudy Outlook for Aerie Pharma's Glaucoma Drug

When an experimental glaucoma drug is only marginally effective, one way to produce positive clinical trial results is to enroll patients with borderline glaucoma.